Press Releases Choose Year All Items 2026 2025 2024 Search Press Releases Found 29 Results April 9, 2026 LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference March 27, 2026 LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) March 26, 2026 LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update March 25, 2026 LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia March 9, 2026 LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors March 4, 2026 LB Pharmaceuticals to Participate in Upcoming March Investor Events February 10, 2026 LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) February 5, 2026 LB Pharmaceuticals Announces $100.0 Million Private Placement January 26, 2026 LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program January 21, 2026 LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel 123»
